5 Topic Commentaries

Clinical Trial Update January 2026

• 

  Martin A. Makary, MD, MPH

  Public health and regulatory science

  •

  U.S. Food and Drug Administration (FDA)

  Providing clarity around modern statistical methods will help sponsors bring more cures and meaningful treatments to patients faster and more affordably.

  Source
• 

  Joel Saltzman, MD

  Medical oncology (gastrointestinal cancers)

  •

  American Society of Clinical Oncology (ASCO); Taussig Cancer Center, Cleveland Clinic

  The addition of FOLFIRI chemotherapy in the frontline setting will give oncologists and patients more options when selecting a first-line regimen.

  Source
• 

  Achille Mileto, MD

  Radiology

  •

  University of Washington School of Medicine; Mayo Clinic CT Clinical Innovation Center (study collaborator)

  The novel dark borosilicate contrast agent has the potential to improve the assessment of numerous pathologies, including the detection of cancer and inflammatory disorders.

  Source
• 

  Jenni Sheng, MD

  Medical oncology (breast cancer)

  •

  Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital

  In the past few years, we’ve had several advances in the expansion of therapeutic options for all breast cancer patients.

  Source
• 

  Mark Schattner, MD, FASGE, AGAF

  Gastroenterology

  •

  Memorial Sloan Kettering Cancer Center

  The use of an endoscopic platform to deliver therapy directly into the tumor is a very exciting and novel approach for treating pancreatic cancer.

  Source